Skip to main content
. Author manuscript; available in PMC: 2016 Aug 16.
Published in final edited form as: Lancet Neurol. 2013 Jan 31;12(3):233–243. doi: 10.1016/S1474-4422(13)70014-0

Figure 2.

Figure 2

Figure 2

Results of the FDG-PET A) The SPM(T) T-maps are illustrated as surface rendering projection showing significant differences follow-up versus baseline of the placebo-treated group, indicating significant decrease of glucose metabolism in green areas (paired t-test, p<0.001, uncorr.; n=8). B) Cluster specifications. C) Changes in CMRglc in these clusters for the different treatment arms as well as placebo (error bars are SEM); ** indicate p<0.01 versus placebo. D) SPM(T) T-maps showing significant differences follow-up versus baseline of low-dose treated patients § (paired t-test, p<0.001, uncorr.; n=12). E) Cluster specifications ¥. F) SPM(T) T-maps showing significant differences at follow-up versus baseline of high-dose treated patients, increases in red, decreases in green areas (paired t-test, p<0.001, uncorr.; n=10). G) Cluster specifications ¥. H) SPM(T) T-maps showing significant differences follow-up versus baseline of all IVIG-treated patients § (paired t-test, p<0.05, FDR-corr.; n=36) J) Cluster specifications ¥.

§ Significant increase of glucose metabolism in red areas. Cluster sizes of >50 voxels are displayed.

¥ Bold markings delineate a cluster, subsequent non-bold markings identify further peaks within the same cluster.